ACESION PHARMA ApS
Core data
Name | ACESION PHARMA ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Dec 15, 2011 |
Employees | 15 |
Locations (P-units) | 1View locations |
Website | https://acesionpharma.com/ |
 LinkedIn | acesion-pharma |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | ACESION PHARMA ApS |
Address | Nordre Fasanvej 215, 2000, Frederiksberg |
Founded | Dec 15, 2011 |
Employees | 15 |
Locations (P-units) | 1View locations |
Website | https://acesionpharma.com/ |
| LinkedIn | acesion-pharma |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of ACESION PHARMA ApS
Description
Acesion Pharma is a Copenhagen-based Danish biotech company developing safer and more effective drug treatments for atrial fibrillation.
Develops antiarrhythmic drugs, including SK ion channel inhibitors, to treat atrial fibrillation.
Company's own description on virk.dk
The activities of Acesion Pharma ApS consist of the development of more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
Products & services
Antiarrhythmic drug development · SK ion channel inhibitors · Drug candidates for atrial fibrillation, including AP30663
Industries
Biotechnology · Pharmaceutical drug development · Cardiovascular medicine
Customer types
Patients with atrial fibrillation
Financials
| Reporting period | |||
|---|---|---|---|
| Gross profit | -35,793,780 | ||
| Operating profit | -46,590,900 | ||
| Profit before tax | -46,723,161 | ||
| Net income | -41,223,161 | ||
| Total assets | 31,475,328 | ||
| Equity | 523,693 | ||
| Avg. employees | 7 | ||
2017–2019 Unlock financial history | |||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From cvr.dk
From acesionpharma.com
| Contact | Phone | |
|---|---|---|
| Main | — | in**@acesionpharma.comShow full |
Gazelle
Loading gazelle status…
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
Founders
| Founder | Registered as founder | Current roles | Ownership |
|---|---|---|---|
| Morten Grunnet | Registered as founderDec 15, 2011 | Current roles — | Ownership — |
| Ulrik Svane Sørensen | Registered as founderDec 15, 2011 | Current roles — | Ownership — |
People
| Person | Roles | Titles |
|---|---|---|
| Jørgen Søberg Petersen | Roles Board | TitlesFORMAND |
| Anders Gaarsdal Holst | Roles Management | TitlesADM. DIR. |
Auditor
No auditor data available
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
| Ownership33.33–49.99 % | Voting rights33.33 % | FromDec 22, 2025 | |
Unknown Other Participant | Ownership20–24.99 % | Voting rights20 % | FromDec 22, 2025 |
Unknown Other Participant | Ownership15–19.99 % | Voting rights15 % | FromDec 22, 2025 |
Unknown Other Participant | Ownership5–9.99 % | Voting rights5 % | FromDec 22, 2025 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| NOVO NORDISK FONDEN | Ownership through | 33.33–49.99 % |
| 🇺🇸Canaan XII L.P. | Ownership through Direct | 20–24.99 % |
| 🇰🇾Alpha Wave Ventures II, LP | Ownership through Direct | 15–19.99 % |
| 🇺🇸RMG-KB BioAccess Fund, L.P. | Ownership through Direct | 5–9.99 % |